With clinical utilization at 8 U.S. Liver Transplant Centers since commercial introduction in January 2022, Paragonix recently showcased its donor liver technology at the 2022 American Transplant Congress
CAMBRIDGE, MASSACHUSETTS – Paragonix Technologies, Inc., a leading organ preservation provider, announced expanded adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts. Since the commercial introduction of the LIVERguard system in January 2022, the advanced donor organ preservation system has been utilized at 8 U.S. transplant centers, including UF Health Shands, one of the largest liver transplant centers in the world. Additionally, Paragonix has been partnering with numerous Organ Procurement Organizations in order to provide more access to this unique hypothermic preservation technology.
The LIVERguard™ System provides a highly controlled, state-of-the art environment for hypothermic liver preservation, coupled with real-time digital monitoring to safeguard a donor liver throughout the transplant journey from donation to transplantation. Like all Paragonix systems, the LIVERguard™ System is paired with a comprehensive digital offering that permits organ tracking, organ monitoring, and the capture of clinical milestones.
This expanded adoption of the LIVERguard system aligns with the first enrollments of the GUARDIAN-LIVER global clinical registry, a comprehensive study that seeks to evaluate a missing piece of the organ procurement process: the impact of methods and technologies used for liver preservation and transportation, and their contribution to the clinical outcome and success of transplant surgery. Patient enrollment in GUARDIAN-LIVER has initiated and Paragonix plans to provide an initial report of the registry’s findings before the end of the year.
“We are excited by the clinical feedback received to date, and we are looking forward to support Liver Transplant Centers transition from an outdated ice-based storage method to our state-of-the art technology offering captured by LIVERguard,” said Lisa Anderson, PhD, President & CEO of Paragonix. “We believe that the clinical community has identified ice transport as a severe limitation to the quality of their critical care and we are positioned to offer a predictable and measurable solution to liver preservation. With the ever-expanding enrollment in the GUARDIAN-Liver Registry, we hope to replicate the exciting results recently announced of our GUARDIAN Heart Study, including a demonstrated improvement 1-Year Survival compared to ice storage, and continue to demonstrate the benefits of advanced organ preservation.”1
L-355, Rev 0